Skip to main content
Year archive

ALTERITY THERAPEUTICS LIMITED — 2023 filings

All 77 regulatory filings released by ALTERITY THERAPEUTICS LIMITED (ATH) in 2023, sourced directly from the official regulator.

77 Filings
2023 Period
2023 filings (77)
Filing Released Lang
Presentation to Extraordinary General Meeting 23 pages 1.9MB
Regulatory Filings
2023-12-28 English
Results of Extraordinary General Meeting 2 pages 322.1KB
Declaration of Voting Results & Voting Rights Announcements
2023-12-28 English
Options Prospectus 23 pages 610.9KB
Capital/Financing Update
2023-12-28 English
SPP Prospectus 33 pages 888.2KB
Capital/Financing Update
2023-12-28 English
Shareholders Approve Tranche Two of Placement and SPP 3 pages 202.1KB
Capital/Financing Update
2023-12-28 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-12-21 English
Alterity Appoints Phillip Hains as Chief Financial Officer 2 pages 185.1KB
Board/Management Information
2023-12-20 English
Notification regarding unquoted securities - ATH 7 pages 30.3KB
Share Issue/Capital Change
2023-12-20 English
Update - Proposed issue of securities - ATH 10 pages 43.4KB
Capital/Financing Update
2023-12-17 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-12-13 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-12-11 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-12-10 English
Ceasing to be a substantial holder 9 pages 155.6KB
Major Shareholding Notification
2023-12-10 English
Grant of Waiver & Addendum - EGM 29 December 2023 3 pages 239.0KB
Regulatory Filings
2023-12-10 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-12-07 English
Change in substantial holding 8 pages 208.3KB
Major Shareholding Notification
2023-12-07 English
Virtual access to Extraordinary General Meeting 29 Dec 2023 2 pages 149.8KB
AGM Information
2023-12-06 English
Becoming a substantial holder 13 pages 258.5KB
Major Shareholding Notification
2023-12-05 English
Positive Efficacy Data for ATH434 in a Primate Model of PD 3 pages 217.2KB
Regulatory Filings
2023-12-03 English
Webcast to Discuss ATH434 Efficacy Data in Primate Model 2 pages 149.8KB
Investor Presentation
2023-12-03 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-11-30 English
Notification of cessation of securities - ATH 4 pages 23.9KB
Share Issue/Capital Change
2023-11-29 English
Notice of Extraordinary General Meeting/Proxy Form 19 pages 662.9KB
Proxy Solicitation & Information Statement
2023-11-29 English
Presentation to Annual General Meeting 26 pages 2.5MB
Regulatory Filings
2023-11-28 English
Chairman's Address 2023 Annual General Meeting 3 pages 253.9KB
AGM Information
2023-11-28 English
Alterity completes Placement Tranche One raising $1.3M 2 pages 215.7KB
Capital/Financing Update
2023-11-28 English
Application for quotation of securities - ATH 6 pages 27.7KB
Capital/Financing Update
2023-11-28 English
Notice Under Section 708A 1 page 92.9KB
Share Issue/Capital Change
2023-11-28 English
Results of Annual General Meeting 2 pages 317.4KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-28 English
ATH presents Novel Biomarker Data for Evaluation of MSA 4 pages 230.9KB
Investor Presentation
2023-11-26 English
Alterity Therapeutics Raises $4.8M AUD in Placement 5 pages 252.1KB
Capital/Financing Update
2023-11-21 English
Proposed issue of securities - ATH 5 pages 27.5KB
Capital/Financing Update
2023-11-21 English
Proposed issue of securities - ATH 8 pages 37.4KB
Capital/Financing Update
2023-11-21 English
Investor Presentation 31 pages 2.7MB
Regulatory Filings
2023-11-21 English
Proposed issue of securities - ATH 10 pages 43.7KB
Capital/Financing Update
2023-11-21 English
Trading Halt 2 pages 162.5KB
Capital/Financing Update
2023-11-19 English
New Data Demonstrating Novel Mechanisms of ATH434 4 pages 3.1MB
Investor Presentation
2023-11-15 English
ATH completes enrolment in ATH434-201 Phase 2 clinical trial 3 pages 219.4KB
Regulatory Filings
2023-11-07 English
Notice of Annual General Meeting/Proxy Form 17 pages 627.3KB
AGM Information
2023-10-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 1.6MB
Interim / Quarterly Report
2023-10-29 English
SEC Form F-3 34 pages 355.9KB
Capital/Financing Update
2023-10-02 English
Notification of cessation of securities - ATH 4 pages 23.9KB
Regulatory Filings
2023-09-12 English
Alterity Form 20-F and XBRL data filed with SEC 2 pages 187.5KB
Report Publication Announcement
2023-08-31 English
Alterity Presents New Data on Multiple System Atrophy 4 pages 224.9KB
Investor Presentation
2023-08-30 English
Appendix 4E and Annual Report 2023 145 pages 2.6MB
Annual Report
2023-08-30 English
Appendix 4G and Corporate Governance Statement 2023 19 pages 533.0KB
Governance Information
2023-08-30 English
Alterity Granted New Composition of Matter Patent in Europe 3 pages 217.7KB
Regulatory Filings
2023-08-22 English
ATH to present New Biomarker data at International Congress 3 pages 212.4KB
Regulatory Filings
2023-08-21 English
Alterity receives a $4.74 million R&D Tax Refund 2 pages 135.7KB
Capital/Financing Update
2023-08-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 517.4KB
Interim / Quarterly Report
2023-07-30 English
Ph 2 Data Monitoring Committee Recommends Continuing Trial 3 pages 220.4KB
Regulatory Filings
2023-07-25 English
Investor Presentation 29 pages 4.1MB
Regulatory Filings
2023-06-21 English
ATH to present at MST Rare Diseases Rich Returns Forum 1
Investor Presentation
2023-06-20 English
ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder 3 pages 218.7KB
Regulatory Filings
2023-05-29 English
First Patient Enrolled in Australia in global Phase 2 Trial 3 pages 219.0KB
Regulatory Filings
2023-05-09 English
Appendix 4C and Quarterly Cash Flow Report 9 pages 558.5KB
Interim / Quarterly Report
2023-04-26 English
bioMUSE Wearable Sensor Data presented at AAN Annual Meeting 4 pages 216.1KB
Regulatory Filings
2023-04-25 English
Notification of cessation of securities - ATH 4 pages 24.4KB
Regulatory Filings
2023-04-10 English
First Patient Enrolled in UK in Phase II Clinical Trial 3 pages 207.8KB
Regulatory Filings
2023-04-03 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification
2023-03-16 English
First Patient Enrolled in USA in Phase II Clinical Trial 3 pages 209.3KB
Regulatory Filings
2023-03-15 English
Application for quotation of securities - ATH 6 pages 27.6KB
Capital/Financing Update
2023-03-15 English
Notice Under Section 708A 1 page 96.4KB
Share Issue/Capital Change
2023-03-15 English
Proposed issue of securities - ATH 5 pages 27.5KB
Capital/Financing Update
2023-03-14 English
US patent grant and license agreement 3 pages 208.5KB
Regulatory Filings
2023-03-13 English
Investor Webinar Presentation 2 pages 178.4KB
Investor Presentation
2023-03-08 English
First Patient Enrolled in Europe in Phase II Clinical trial 3 pages 208.6KB
Regulatory Filings
2023-03-07 English
Half Yearly Report and Accounts 27 pages 857.9KB
Regulatory Filings
2023-02-27 English
Regulatory approval for Phase II trial in France and Austria 3 pages 209.9KB
Regulatory Filings
2023-02-15 English
Change in substantial holding 5 pages 1.5MB
Major Shareholding Notification
2023-02-14 English
Notification of cessation of securities - ATH 4 pages 24.2KB
Share Issue/Capital Change
2023-01-31 English
Appendix 4C and Quarterly Cash Flow Report 9 pages 604.1KB
Interim / Quarterly Report
2023-01-30 English
ATH434 Prevents Brain Cell loss in Parkinsons Animal Model 3 pages 257.7KB
Regulatory Filings
2023-01-29 English
ATH434 Clinical Trial Launched in Italy 3 pages 230.9KB
Regulatory Filings
2023-01-24 English
ATH434 clinical trial launched in the US 3 pages 232.5KB
Regulatory Filings
2023-01-08 English
ADS ratio change 2 pages 197.8KB
Capital/Financing Update
2023-01-05 English
Alterity to participate in Sachs Neuroscience Conference 2 pages 175.3KB
Investor Presentation
2023-01-02 English